INTUNIV
Generic Name and Formulations:
Guanfacine (as HCl) 1mg, 2mg, 3mg, 4mg; ext-rel tabs.
Company:
Shire US, Inc.
Indications for INTUNIV:
Attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications.
Adult Dose for INTUNIV:
≥18yrs: not established.
Children's Dose for INTUNIV:
Swallow whole with water, milk, or other liquid. Do not give with high-fat meals. <6yrs: not recommended. 6–17yrs: Initially 1mg once daily; titrate by 1mg/day at 1-week intervals; usual max 4mg once daily. Monotherapy: improvements seen at doses of 0.05–0.08mg/kg once daily; doses up to 0.12mg/kg once daily may provide additional benefit. Adjunctive therapy: optimal dosage range: 0.05–0.12mg/kg/day. Reeva luate periodically. Withdraw gradually (by 1mg every 3–7days).
Pharmacological Class:
Central alpha-2A agonist.
Contraindications:
Concomitant use with other forms of guanfacine.
Warnings/Precautions:
Do not substitute with other forms of guanfacine on a mg-mg basis. Concomitant antihypertensives, other risks for hypotension, syncope, bradycardia, cardiovascular disease. Monitor heart rate, BP. Dehydration. Elevated temperature. Renal or hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
Interactions:
May be potentiated by CYP3A4/5 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers (eg, rifampin). May potentiate valproic acid. Additive effects with other antihypertensives, CNS depressants (eg, benzodiazepines, antipsychotics, barbiturates).
Adverse Reactions:
Somnolence, sedation, fatigue, nausea, lethargy, hypotension, insomnia, dizziness, abdominal pain, dry mouth, constipation; bradycardia.
How Supplied:
Tabs—100 |
